Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
iRhythm Technologies Inc Market Cap
Based on ratings from 13 stock analysts, the iRhythm Technologies Inc stock price is expected to increase by 14.17% in 12 months. This is calculated by using the average 12-month stock price forecast for iRhythm Technologies Inc. The lowest target is $79 and the highest is $125. Please note analyst price targets are not guaranteed and could be missed completely.
IRTC is a stock in Healthcare which has been forecasted to be worth $97.25 as an average. On the higher end, the forecast price is $125 USD by Suraj Kalia from Oppenheimer and on the lower end IRTC is forecasted to be $79 by Mike Polark from Baird.
These are the latest 20 analyst ratings of IRTC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Nathan Treybeck Wells Fargo | Equal-Weight | $86 | Reinstates | Dec 3, 2024 |
| Mike Polark Baird | Outperform | $79 | Maintains | Nov 1, 2024 |
| David Saxon Needham | Buy | $96 | Maintains | Oct 31, 2024 |
| Richard Newitter Truist Securities | Buy | $95 | Maintains | Oct 22, 2024 |
| Richard Newitter Truist Securities | Buy | $80 | Maintains | Oct 14, 2024 |
| David Roman Goldman Sachs | Neutral | $78 | Initiates | Oct 4, 2024 |
| William Plovanic Canaccord Genuity | Buy | $137 | Maintains | Sep 25, 2024 |
| Joanne Wuensch Citigroup | Buy | $110 | Maintains | Aug 22, 2024 |
| David Saxon Needham | Buy | $119 | Maintains | Aug 2, 2024 |
| Richard Newitter Truist Securities | Buy | $117 | Reiterates | Aug 2, 2024 |
| Allen Gong JP Morgan | Overweight | $100 | Maintains | Aug 2, 2024 |
| Suraj Kalia Oppenheimer | Outperform | $145 | Maintains | Aug 2, 2024 |
| Mike Polark Baird | Outperform | $110 | Maintains | Aug 2, 2024 |
| David Rescott Truist Securities | Buy | $134 | Maintains | Jul 16, 2024 |
| Cecilia Furlong Morgan Stanley | Overweight | $130 | Maintains | Jul 15, 2024 |
| Mike Polark Wolfe Research | Outperform | $115 | Upgrade | Jun 20, 2024 |
| William Plovanic Canaccord Genuity | Buy | $122 | Maintains | May 3, 2024 |
| David Saxon Needham | Buy | $138 | Maintains | May 3, 2024 |
| William Plovanic Canaccord Genuity | Buy | $133 | Maintains | Feb 23, 2024 |
| David Saxon Needham | Buy | $137 | Maintains | Feb 23, 2024 |
When did it IPO
2016
Staff Count
2,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Quentin S. Blackford
Market Cap
$2.67B
In 2023, IRTC generated $492.7M in revenue, which was a increase of 19.90% from the previous year. This can be seen as a signal that IRTC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iRhythm Technologies, Inc. (NASDAQ: IRTC) will participate in the Citi 2024 Global Healthcare Conference, focusing on its digital health solutions for disease detection and prevention.
Why It Matters - iRhythm Technologies' participation in a major healthcare conference suggests potential for increased visibility, networking, and investor interest, impacting stock performance and market perception.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Five new studies on LTCM devices focus on digital engagement, arrhythmia patterns, and the economic impact of early arrhythmia detection in type 2 diabetes and COPD patients.
Why It Matters - Advancements in LTCM device studies may enhance patient outcomes and reduce healthcare costs, potentially driving demand and profitability for companies in this sector.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iRhythm Technologies, Inc. (NASDAQ: IRTC) will participate in the Wolfe Research 2024 Healthcare Conference, highlighting its focus on digital health solutions for disease detection and prevention.
Why It Matters - iRhythm's participation in a major healthcare conference could enhance its visibility, attract potential investors, and signal growth opportunities in the digital health sector.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - iRhythm Technologies, Inc. (NASDAQ: IRTC) will hold its Q3 2024 results conference call on October 30, 2024, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters - The earnings call signals iRhythm's performance update, crucial for assessing financial health, growth potential, and market sentiment, impacting stock valuation and investment decisions.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iRhythm Technologies, Inc. (NASDAQ: IRTC) reported its Q3 2024 financial results on October 30, 2024, focusing on digital health solutions for disease detection and prevention.
Why It Matters - iRhythm's financial results may indicate its growth trajectory and market position, influencing investor confidence and stock performance in the digital health sector.
Fri, 01 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Bragar Eagel & Squire is investigating potential claims against iRhythm Technologies (NASDAQ: IRTC) for possible fiduciary duty breaches by its board, stemming from a class action filed in February 2024.
Why It Matters - The investigation into iRhythm Technologies may signal potential legal issues and governance concerns, which could negatively impact stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
